ArticleFolia microbiologica2026
Effects of Pseudevernia furfuracea (L.) Zopf on Helicobacter pylori induced gastritis in rats: anti- Helicobacter pylori and anti gastritis properties.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the antimicrobial and host-directed effects of Pseudevernia furfuracea (L.) Zopf (P. furfuracea) against Helicobacter pylori (H. pylori) associated gastritis. The acetone extract inhibited H. pylori growth in vitro, with a minimum inhibitory concentration (MIC) of 15.625 µg/mL, and modestly reduced pre-formed biofilms. In a rat model of indomethacin- and H. pylori induced gastritis, oral P. furfuracea treatment lowered gastric bacterial load and urease activity, shifted the cytokine profile toward an anti-inflammatory pattern (reduced interleukin-1β [IL-1β] and restored interleukin-10 [IL-10]), improved oxidative status (decreased malondialdehyde [MDA] and total oxidant status [TOS], increased reduced glutathione [GSH] and total antioxidant status [TAS]), and downregulated hypoxia-inducible factor-1α (HIF-1α) and transforming growth factor-β (TGF-β) transcripts. These molecular and biochemical changes were accompanied by better preservation of gastric mucosal architecture and reduced inflammatory cell infiltration. Overall, P. furfuracea exhibited a dual profile, combining direct anti H. pylori activity with mucosa-protective, host-directed effects. These findings support further development of standardized P. furfuracea preparations, including mechanistic, phytochemical, and dose–response studies, as potential adjuncts to conventional H. pylori therapies.
Indexed as
Identifiers
41642557What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.